Seattle Genetics' Adcetris (brentuximab vedotin) Receives FDA's Breakthrough Designation for Frontline Peripheral T-Cell Lymphomas
Shots:
- The FDA’s BT designation is based on P-III ECHELON-2 study results assessing Adcetris + CHP vs CHOP (cyclophosphamide- doxorubicin- vincristine- prednisone) in 450 patients with CD30+ T-cell lymphoma across North America- EU and Asia
- The P-III ECHELON-2 study results: met it's 1EPs & 2EPs; improvement in PFS- superior OS; CRR and ORR were statistically significant in favor of the Adcetris + CHP arm; safe & effective
- Adcetris (brentuximab vedotin- IV) is an ADC with anti-CD30 mAb- co-developed by Seattle Genetics and Takeda and has received FDA’s approval for 5 indications including r/r CD30+ Hodgkin lymphoma following ASCT- r/r sALCL- CD30+ CTCL
Ref: Seattle Genetics | Image: ValueWalk
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.
